biogen

new CMO- was run out of sanofi due to a personality disorder issues, referred to as "evil" watch your back with this one !!!!

Does anyone know who the managers are for the expansion?

The analysts started scratching their heads during an earnings conference call as there was a lack of clarity in the delay in filing of Biogen's Alzheimer's drug. Last year, Biogen stock soared by 27% after the company optimistically said it would file an application with the US Food and Drug...

Wonder what’s up with Daniel Karp. Got the word he left. He’s like the third recent senior level executive to leave. Kind of scary

Biogen reported second-quarter earnings that surpassed Wall Street expectations. The company reported adjusted earnings of $9.15 per share, way ahead of the street projection of $7.53 per share. On a GAAP basis, earnings grew 88% to $7.85 per share. Revenue grew 8% to $3.62 billion, surpassing...

I know there is information on benefits, etc. but some items are not answered. Does Biogen do company cars or an allowance? Is the insuramce and premiums by the company pretty fair/average?Also, do they do Amex or do they have Visa business cards? Are you allowed to keep the points for those and...

Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease. Will it succeed and create a drug to cure Alzheimer's disease?

Hi all, 1. Does anyone knows how many account executives are there and are they happy with the role which looks bit integrated with other things? 2. For how many regions, the account executives are recruited/available? Thanks

Hi all, Can someone please explain me the difference between TLL (Thought Leader Liaison) and MSL? Who do these two positions report to and what are the differences in the roles? Thanks Sol

It seems the Alzheimers data has dominated the earnings ! And SPINRAZA as expected contributing much to revenues. https://news.alphastreet.com/biogen-stock-gains-on-upbeat-q2-results/

Shares of biotech company Biogen (BIIB) rallied on Thursday during the after-hours trading after the company said it achieved positive results from final analysis of its Phase II trial of an Alzheimer’s drug. The advanced drug candidate, BAN2401, was developed in partnership with a Tokyo-based...

Gilead Sciences (GILD) reported a 43% dip in earnings for the first quarter due to lower product sales and prescription trends. Higher competition and lower sales of certain hepatitis C products too impacted sales during the quarter. Infographics of the results. The market has huge hopes for...

Biogen, whose shares fell nearly 16.5% this year, saw it further dip 2.4% to $259.30 in pre-market trade, despite the strong first-quarter earnings. Earnings, excluding items, jumped to $6.05 per share this quarter from last year’s $5.20 per share. On a diluted basis, Biogen reported earnings of...

A trial testing Revlimid on follicular lymphoma did not meet the desired endpoint. Biogen's RITUXAN also fails..

Not sure if you youngsters will remember, but the Tecfidera launch was (without a doubt) a great success. Resources should be allocated the same way to drive success for the Spiranza.